Long-term follow-up after a vision gene eye injection
Part of Eyes & vision, Genetic & congenital clinical trials.
This study checks how people who previously received a gene therapy eye injection (vMCO-I) are doing over the long term. It may help researchers understand long-lasting effects and safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have received vMCO-I in an earlier (parent) study
- That earlier vMCO-I treatment must have been given as an eye injection
- You must be willing and able to give consent for this follow-up study
- If you do not agree to participate, you cannot join
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy called VG901, given as an injection into the eye, for people with retinitis pigmentosa caused by a specific genetic change in the CNGA1 gene. The goal is to see if it is safe and tolerable.
This study tests a gene-editing drug, ZVS203e, injected into one eye to see if it is safe and tolerable for people with retinitis pigmentosa caused by a specific genetic change in the RHO gene. It may help slow vision loss or improve vision, but the main goal is to check safety.
This study tests whether a single injection of umbilical cord stem cells around the eye can safely help slow or improve vision loss from retinitis pigmentosa, a genetic eye disease. It also checks how long any benefits might last, using regular eye tests and a quality-of-life survey.
This trial tests an eye injection called KIO-301 for people with late-stage retinitis pigmentosa (a genetic eye disease that causes vision loss). The goal is to see if it can improve vision or slow further vision loss.
This trial tests a new gene therapy called ZVS203e for people with retinitis pigmentosa caused by a specific RHO gene mutation. It aims to see if the treatment is safe and can help improve vision.
This study looks at the safety and effectiveness of giving the gene therapy treatment to your other eye, after you've already had it in one eye and been followed for a year. It may help improve vision in the untreated eye.
Hear when a new Retinitis Pigmentosa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.